TCRX Insider Trading Activity and SEC Form 4 Filings
TCRX insider trading summary
Over the past 12 months, insiders at TScan Therapeutics, Inc. (TCRX) reported 6 open-market purchases worth $291K by 2 insiders and no sales on SEC Form 4. Net insider buying was $291K.
Latest TCRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 23, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy | $6K (6,232 @ $0.90) |
| Dec 23, 2025 | Weston Nichols | 10% Owner | Buy | $6K (6,232 @ $0.90) |
| Dec 22, 2025 | Weston Nichols | 10% Owner | Buy | $68K (75,500 @ $0.90) |
| Dec 22, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy | $68K (75,500 @ $0.90) |
| Dec 19, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy | $72K (80,069 @ $0.90) |
| Dec 19, 2025 | Weston Nichols | 10% Owner | Buy | $72K (80,069 @ $0.90) |
| May 20, 2025 | Weston Nichols | 10% Owner | Buy | $1.4M (1,200,000 @ $1.20) |
| May 20, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy | $1.4M (1,200,000 @ $1.20) |
| May 19, 2025 | Weston Nichols | 10% Owner | Buy | $1.7M (1,388,794 @ $1.20) |
| May 19, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy | $1.7M (1,388,794 @ $1.20) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.